Eos/Pharmacopeia merger terminated
Executive Summary
Eos and Pharmacopeia will continue to jointly own all compounds developed from the December transfer of Eos' therapeutic antibody target AAB1 to Pharmacopeia following termination of merger plans (1"The Pink Sheet" Aug. 27, 2001, p. 28)...